By designing new tools that can analyze huge libraries of immune cells and their targets, Michael Birnbaum hopes to generate better T cell therapies for cancer and other diseases.
Alnylam Pharmaceuticals, founded by MIT professors and former postdocs, has turned the promise of RNAi research into a new class of powerful therapies.
MIT spinout 247Solar is building high-temperature concentrated solar power systems that use overnight thermal energy storage to provide power and heat.
The former vice chancellor for undergraduate and graduate education will leverage more than 30 years of experience at the Institute to oversee MIT’s research activities.
MIT spinout Strand Therapeutics has developed a new class of mRNA molecules that can sense where they are in the body, for more targeted and powerful treatments.